187 In the index

Cerebrolysin CERE

A drug made from processed animal-brain proteins, used by prescription in some countries (mostly in Europe and Asia) for stroke recovery and dementia. Human trials show mixed but sometimes encouraging results for recovery and thinking, though it isn't approved in the U.S. and the evidence isn't as strong as for standard treatments.

Also known as FPF-1070

Effects Focus Heal

Routes Injectable

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 5 mL/day

Reported range 5-30 mL/day

Route Intravenous or intramuscular injection

Frequency Once daily

Duration 10-20 day course, often repeated periodically

Approved and used clinically outside the US (e.g., parts of Europe and Asia) for stroke/dementia; not FDA-approved. Sold in the US only as an unregulated import.

Where this comes from Clinical trials outside the US

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.